dont expect lot new news today
 reiter overw eight rate axon expect new new gener manag call
seri today et ith brook stori vice-president gener manag pelv ic gastric therapi
expect call
like focu ill sacral neuromodul snm busi total sale though also
includ reflux franchis barrx
mostli prepar remark ith smaller portion dedic moreov expect select
reiter timelin upcom snm product interstim micro target approv
discuss constant current vs constant voltag interstim ii constant voltag herea interstim micro ill constant current
 hich similar axon r-snm system
call overhang share possibl capit rais ith pass tw event
 eek mdt call capit rais believ market focu hat lie aheadmarket share gain
monopoli sacral neuromodul market year sacral neuromodul market readi
new entrant innovationand entrant axon innov r-snm system
contact us call info
 oo bloomberg im reach via im email call ith question kristen
inform axon see follow notes/report
 oab approv race realli begin
reiter overw eight ahead immin approv anoth physician seminar
readi set go oab day physician seminar takeaw ay reit ow note review takeaw ay axon
physician seminar attend
address innov void initi ith overw eight rate note initi report contain background
inform compani review landscap snm
model post barclay live model link
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog valu axn ev/sal basi price target appli multipl sale estim
million hich compar smid cap high grow th med-tech compani
risk may imped achiev barclay research valuat price risk includ time
adopt clinician abil penetr market competit product approv time line launch particularli
interstim micro fda manufactur issu recal also risk factor reimburs chang
rate price target histori
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli target pe calendar ep estim discount med-tech compani
trade hich believ appropri given slow er grow th profil grow th profil improv expect
pe expand
risk may imped achiev barclay research valuat price nside risk includ fx rate
strengthen us dollar hich could pressur earn stock perform new product key futur success
compani thu extent compani unabl receiv fda approv could advers impact futur
outlook product includ compani surgic robot platform hich expect regulatori approv outsid unit
state begin key product includ micra av interstim micro minim futur iter continu blood
glucos monitor devic transcathet valv system upsid greater success ith new product margin expans
risk includ signific reimburs chang competit pressur product failur fda govern
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
